---
title: "\"Performance\" CR MEDICAL's mid-term net profit of 340 million RMB fell by 21.8%, with a dividend of 5 cents"
description: "CR MEDICAL announced its interim results for the six months ending in June, with revenue of RMB 4.525 billion, a year-on-year decrease of 9.1%. It recorded a net profit of RMB 340 million, down 21.8%,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254663042.md"
published_at: "2025-08-26T15:18:48.000Z"
---

# "Performance" CR MEDICAL's mid-term net profit of 340 million RMB fell by 21.8%, with a dividend of 5 cents

> CR MEDICAL announced its interim results for the six months ending in June, with revenue of RMB 4.525 billion, a year-on-year decrease of 9.1%. It recorded a net profit of RMB 340 million, down 21.8%, with earnings per share of 27 cents. The interim dividend remains at 5 cents

CR MEDICAL (01515.HK) announced its interim results for the six months ending in June, with revenue of RMB 4.525 billion, a year-on-year decrease of 9.1%. It recorded a net profit of RMB 340 million, down 21.8%, with earnings per share of 27 cents. The interim dividend remains at 5 cents

### Related Stocks

- [01515.HK - CR MEDICAL](https://longbridge.com/en/quote/01515.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美团：本集团预期 2025 年度录得亏损约人民币 233 亿元至人民币 243 亿元 | 美团预计 2025 年度将录得亏损约人民币 233 亿元至 243 亿元，而 2024 年度则录得溢利约 358.08 亿元。预期亏损主要源于核心本地商业分部的经营溢利从 2024 年的约 524.15 亿元转为 2025 年的约 68 亿 | [Link](https://longbridge.com/en/news/275897016.md) |
| Allscripts 医疗｜8-K：2025 财年营收 5.87 亿美元 |  | [Link](https://longbridge.com/en/news/276168463.md) |
| 英格索兰｜10-K：2025 财年营收 76.51 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276172246.md) |
| AIRSHIP AI HOLDINGS INC C/WTS 21/12/2028(TO PUR COM)｜10-K：2025 财年营收 15.32 百万美元 |  | [Link](https://longbridge.com/en/news/276134447.md) |
| Quad Graphics｜8-K：2025 财年营收 24.2 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276171554.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.